Featured
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
Arctic Vision is a specialty ophthalmology company based in China that has the exclusive license for commercialization and development of XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which they refer to as ARCATUS, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries.
Kyowa Kirin to Acquire Orchard Therapeutics
Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, and Orchard Therapeutics plc (Orchard Therapeutics, Nasdaq: ORTX), a global gene therapy leader, today announced the companies have entered into a definitive agreement under which Kyowa Kirin will acquire Orchard Therapeutics
Sanofi, Teva sign deal worth $1.5 billion to co-develop blockbuster inflammatory bowel disease drug
French drug maker Sanofi has announced that it is teaming up with Israel-based Teva Pharmaceuticals to co-develop an anti-TL1A therapeutic for inflammatory bowel disease in a deal worth up to $1.5 billion.
上海浦东新区：推动产业与资本对接 打造生物医药世界级产业集群
上证报中国证券网讯 上海市政府今日举办新闻发布会，介绍2023上海国际生物医药产业周的有关情况。上海市浦东新区副区长吴强在会上表示，浦东新区将通过更高水平的科技创新和资本要素融合，助力浦东打造生物医药世界级产业集群。主要举措包括：
Precision Neuroscience wins FDA breakthrough nod for BCI, buys factory in Texas
Precision Neuroscience announced today that its brain-computer interface (BCI) technology won FDA breakthrough device designation.
Sanofi Is Exploring Acquisition of Cancer Drugmaker Mirati
French pharmaceutical firm Sanofi is exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc., according to people familiar with the matter.
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Bristol Myers Squibb (NYSE: BMY) and Mirati Therapeutics, Inc.® (NASDAQ: MRTX) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion.
Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments
“ALSP has long been interested in helping to drive biopharma innovation emerging in Singapore,” said Alice Chen, Executive Vice President at ALSP and Automera board member.
Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the U.S. Food and Drug Administration (FDA) has granted Tetra Therapeutics Inc. (hereafter "Tetra"), a Shionogi Group Company, Rare Pediatric Disease Designation for zatolmilast (BPN14770), an investigational treatment being studied for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism.
Triastek Completes USD 20.4 Million Pre-C Funding Round to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and Products
Triastek, Inc. ("Triastek") today announced the completion of a USD 20.4 million Pre-C financing round. This milestone marks a significant step in the advancement of Triastek's innovative solutions for drug development and manufacturing.
